{"id":"NCT00295646","sponsor":"Austrian Breast & Colorectal Cancer Study Group","briefTitle":"Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid","officialTitle":"Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid, in Premenopausal, Hormone Receptor-positive Breast Cancer Patients (Stage I, II)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1999-06","primaryCompletion":"2008-03-27","completion":"2018-06-26","firstPosted":"2006-02-24","resultsPosted":"2024-03-15","lastUpdate":"2024-03-15"},"enrollment":1803,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"tamoxifen","otherNames":["Nolvadex"]},{"type":"DRUG","name":"anastrozole","otherNames":["Arimidex"]},{"type":"DRUG","name":"zoledronic acid","otherNames":["Zoledronate, Zometa"]},{"type":"OTHER","name":"goserelin","otherNames":[]}],"arms":[{"label":"AZ (Arimidex+Zoledronate)","type":"ACTIVE_COMPARATOR"},{"label":"TZ (Tamoxifen+Zoledronate)","type":"ACTIVE_COMPARATOR"},{"label":"AC (Arimidex Control)","type":"ACTIVE_COMPARATOR"},{"label":"TC (Tamoxifen Control)","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective is, first, the comparison of tamoxifen and anastrozole and, second, the comparison of zoledronate added to standard adjuvant therapy with controls according to disease-free survival (DFS) in premenopausal patients with non-metastatic breast cancer treated with tamoxifen or anastrozole. To assess whether zoledronate added to standard adjuvant therapy can decrease or even prevent bone loss in patients treated with hormonal blockade combined with an antiestrogen or aromatase inhibitor.","primaryOutcome":{"measure":"Comparison of Anastrozole vs Tamoxifen in Premenopausal Patients With Non-metastatic Breast Cancer With Respect to Disease-free Survival (DFS)","timeFrame":"Time from randomization to the analysis data cut-off date when 124 DFS events had occurred. On the analysis data cut-off date, maximum time on study per patient was 102 months.","effectByArm":[{"arm":"AZ (Arimidex+Zoledronate)","deltaMin":null,"sd":null},{"arm":"TZ (Tamoxifen+Zoledronate)","deltaMin":null,"sd":null},{"arm":"AC (Arimidex Control)","deltaMin":null,"sd":null},{"arm":"TC (Tamoxifen Control)","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001 vs OG002 vs OG003","p":"0.59"}]},"eligibility":{"minAge":"19 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":72,"countries":["Austria","Germany"]},"refs":{"pmids":["18718815","17159195","19213681","19561003","20567005","21641868","22084643","21555684","21417849","22730099","23749244","25403582","26211824","19804020","38979716","36592505"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":67,"n":450},"commonTop":["Bone pain","Other/minor (not categorized)","Arthralgia","Fatigue","Psychological disorder NOS"]}}